Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster II
- 10:30AM-12:30PM
-
Abstract Number: 1622
18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis
- 10:30AM-12:30PM
-
Abstract Number: 1634
A Lexicon of Signs and Symptoms of Giant Cell Arteritis: An International Expert Consensus
- 10:30AM-12:30PM
-
Abstract Number: 1640
ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis
- 10:30AM-12:30PM
-
Abstract Number: 1613
Adherence to Dietary Recommendations and the Risk of Developing Giant Cell Arteritis; A Nested Case-Control Study
- 10:30AM-12:30PM
-
Abstract Number: 1636
Age-associated B Cells Contribute to Inflammation of Takayasu’s Arteritis in an Antibody-secreting Cell Differentiation Independent Manner
- 10:30AM-12:30PM
-
Abstract Number: 1621
Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study
- 10:30AM-12:30PM
-
Abstract Number: 1612
Arterial Involvement Distribution on 18FFDG PET-CT in Giant Cell Arteritis: Variances Based on Clinical Phenotype
- 10:30AM-12:30PM
-
Abstract Number: 1633
Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients
- 10:30AM-12:30PM
-
Abstract Number: 1638
Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis
- 10:30AM-12:30PM
-
Abstract Number: 1619
Challenges in Managing Polymyalgia Rheumatica and Giant Cell Arteritis: Steroid Dependence and Preventive Care
- 10:30AM-12:30PM
-
Abstract Number: 1618
Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis
- 10:30AM-12:30PM
-
Abstract Number: 1630
Disease Manifestations, Diagnostic Findings, and Mortality of 120 Consecutive Patients Suspected of Giant Cell Arteritis – Results from a Hospital GCA Fast-Track Clinic
- 10:30AM-12:30PM
-
Abstract Number: 1637
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
- 10:30AM-12:30PM
-
Abstract Number: 1625
Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis
- 10:30AM-12:30PM
-
Abstract Number: 1626
Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review
- 10:30AM-12:30PM
-
Abstract Number: 1615
Is Regular Vascular Imaging Scheduled Essential in the Follow-Up of Takayasu Arteritis? A Large-Scale Multicenter Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 1635
Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management
- 10:30AM-12:30PM
-
Abstract Number: 1614
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
- 10:30AM-12:30PM
-
Abstract Number: 1632
Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?
- 10:30AM-12:30PM
-
Abstract Number: 1641
Orbital MRI as a Promising Approach for the Diagnosis of Giant Cell Arteritis in Case of Anterior Ischemic Optical Neuropathy or Central Retinal Artery Occlusion
- 10:30AM-12:30PM
-
Abstract Number: 1617
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
- 10:30AM-12:30PM
-
Abstract Number: 1624
Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement
- 10:30AM-12:30PM
-
Abstract Number: 1627
Real-World Data on Imaging Tests, Specifically Temporal Artery Ultrasound, in Giant Cell Arteritis in Japan: A Multicenter Retrospective Study
- 10:30AM-12:30PM
-
Abstract Number: 1631
Serum IL-6 Levels Correlate with Inflammatory Activity in Computerized Tomography Angiography Scans in Takayasu Arteritis
- 10:30AM-12:30PM
-
Abstract Number: 1623
Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
- 10:30AM-12:30PM
-
Abstract Number: 1629
Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis
- 10:30AM-12:30PM
-
Abstract Number: 1628
Tocilizumab for Giant Cell Arteritis in Japan over 2 Years: A Multicenter Retrospective Study
- 10:30AM-12:30PM
-
Abstract Number: 1639
Ultrasound Fast-Track Giant Cell Arteritis Clinic Experience in the United States
- 10:30AM-12:30PM
-
Abstract Number: 1620
Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse
- 10:30AM-12:30PM
-
Abstract Number: 1616
Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis